The epidemiology of pulmonary arterial hypertension (PAH) in patients with heart failure (HF) is poorly described. Our aim was to investigate the determinants and prognostic significance of PAH in a large representative outpatient population with HF.
Introduction
Pulmonary arterial (PA) pressure may be increased in heart failure (HF) and is associated with more severe symptoms and worse outcomes. 1 Pulmonary arterial hypertension (PAH) can be defined as a mean PA pressure .25 mmHg at rest, 2 measured invasively by right heart catheterization, and can be detected non-invasively with Doppler echocardiography that allows PA systolic pressure (PASP) to be estimated from the peak velocity of tricuspid regurgitation (TRV). A PASP of .35 mmHg is used to define mild PAH. 2 However, PASP increases with age and body mass index (BMI) 3 and a higher threshold for diagnosing PAH may be more appropriate for older patients with HF. However, the threshold definition of PAH is important as it will determine the prevalence of PAH and may be used to guide prognosis and future treatment. Previous reports have focused on the determinants of PAH, its prevalence, and its effect on prognosis in selected groups of patients with HF. 1,4 -7 However, in these studies, patients with clinically obvious COPD were often excluded, lung function was not routinely assessed and the diagnosis of COPD lacked precision. 4 Chronic obstructive pulmonary disease and HF commonly co-exist and their respective roles for the development of PAH in HF remain unclear. We studied the prevalence, determinants, and prognostic impact of PAH among consecutive patients referred for the diagnosis or exclusion of suspected HF. We also aimed to determine a value of PASP that might be used to define a population at high risk who might be candidates for treatments targeted at PAH.
Methods Study population and procedures
The patients enrolled were referred for the evaluation of suspected HF, predominantly exertional breathlessness, between August 2001 and May 2008 by local primary and secondary care physicians serving a population of about 560 000 in Kingston-upon-Hull and the East Riding of Yorkshire, UK.
All patients were clinically evaluated and had a 6 min walk test, electrocardiogram, blood tests, spirometry, and echocardiogram.
Heart failure was defined as the presence of an appropriate history and symptoms and either left ventricular ejection fraction (LVEF) ≤ 45% [LV systolic dysfunction (LVSD)] or LVEF . 45% together with N-terminal pro-brain natriuretic peptide (NT-proBNP) ≥ 50 pmol/L (≥423 pg/mL) (preserved systolic HF or PS-HF). Ischaemic heart disease (IHD) was defined as a previous myocardial infarction, coronary bypass surgery, or coronary disease on angiography. Patients underwent spirometry (Vitalograph, Vitalink w , UK). Forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC) were measured. Chronic obstructive pulmonary disease was defined as 'absent or mild' if the FEV 1 /FVC ratio was .70% and 'worse than (.) mild' if the FEV 1 /FVC ratio was ,70% together with measured FEV 1 , 80% predicted. 8 Patients with atrial fibrillation or atrial flutter were grouped as 'AF'.
Echocardiographic measurements
Transthoracic echocardiography examinations were performed following the recommendations of the British Society of Echocardiography 9 using a Vivid Five (GE Healthcare, UK) system. Echocardiograms were reviewed, blind of patients' clinical information, by a single operator (T.D.) using an EchoPAC station (GE Healthcare). The average of three measurements was used in patients in sinus rhythm and five in patients in AF. Left ventricular ejection fraction was measured using Simpson's biplane method or, if measurements were technically not possible [n ¼ 49, 12% of the patient with right ventricular tricuspid pressure gradient (RVTG)], LVSD was graded using a subjective scale of normal/mild/mild to moderate/moderate/moderate to severe and severe where 'normal to mild' was assumed to be equivalent to LVEF . 45%. The LV end-diastolic volume was indexed to the body surface area (LVEDV ind ). Tricuspid regurgitation area was measured during the review of echoes. Tricuspid regurgitation was classified as mild or less if TR area was ,5 cm 2 , severe if TR area .10 cm 2 , and moderate between these limits. 9 To estimate TR prevalence, the scale was abbreviated to: none/≤mild and .mild ( Figure 1 ). The maximum peak velocity of TR was measured using continuous Doppler (Figure 1 ). The maximum peak velocity was not clearly delineated in 44 patients who were thereafter considered not to have had an RVTG measurement. Trans-tricuspid gradient (RVTG, mmHg) was estimated from the modified Bernoulli equation 10 as RVTG ¼ 4 × (peak TR velocity). 2 Right ventricular tricuspid pressure gradient can be considered equal to the PASP after adding the estimated mean right atrial pressure of 10 mmHg 11 in the absence of RV outflow tract obstruction. We did not measure inferior vena cava size and its respiratory variation as it is poorly related to mean right atrial pressure. 12 Tricuspid annular plane systolic excursion and RV end-diastolic area were measured to evaluate RV systolic function and dimension. Mitral regurgitation (MR) was quantified by measuring the area of the colour Doppler signal divided by the left atrial (LA) area measured in the four-chamber view. Mitral regurgitation was considered 'mild or less' if MR area/ LA area was ,10%, 'severe' if MR area/LA area was .40%, and moderate if between the two. Left atrial volume was measured in the four-chamber view and indexed to the body surface area (LA ind ). Peak mitral early diastolic velocity (E, m/s), the E-wave deceleration time (DCT, ms), and the velocity at atrial contraction (A, m/s) were measured using pulsed-wave Doppler. Left ventricular filling pressure classes were defined in accordance with the ASE 2009 guidelines. 13 In LVSD patients: raised LV filling pressure was defined as E/A ≥ 2 if in sinus rhythm or DCT , 150 ms if in AF; normal LV filling pressure was defined as E/A , 1 in patients in sinus rhythm or DCT ≥ 200 ms for those in AF; patients between these limits were classed as undetermined. In PS-HF patients, LV filling pressure was classified using the LA volume indexed to body surface area as follows: raised LV filling pressure if LA ind . 34 mL/m 2 and normal LV filling pressure if LA ind ≤ 34 mL/m 2 .
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Ethics
The investigation conforms to the principles outlined in the Declaration of Helsinki. It was approved by the Hull and East Yorkshire Research Ethics Committee. All subjects gave their written informed consent.
Statistical analysis
The population was divided into quartiles by RVTG, and then into two groups after determining the best RVTG cut-off value to predict mortality. to compare categorical data. Independent clinical and echocardiogaphic determinants of RVTG were assessed using logistic regression with backward elimination of independent variables based on likelihood-ratio tests. The probability of death at 12 months was assessed as a continuous function of RVTG using a moving average estimator. The size of the averaging window was set to 10% of the available observations. The resultant curve was smoothed using a best-fit polynomial equation. Multivariable Cox's proportional hazard analysis was used to test the prognostic value of variables. Independent prognostic factors were identified by a backward stepwise selection algorithm. Six models were tested. The Kaplan -Meier plots were used to present survival curves and the log-rank test was used. Analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). P-values were considered significant if ,0.05.
Determinants and prognostic value of PAH in HF patients
Results
Distribution
Of 2100 patients enrolled (Figure 1) , HF was diagnosed in 1380 patients and was due to LVSD in 74%, in whom TR was present in 59% and RVTG could be measured in 26%; and due to PS-HF in 26%, in whom TR was present in 65% and RVTG could be measured in 40%. In addition, TR was present in 36% of the patients who were not diagnosed with HF and RVTG could be measured in 13% of these. Right ventricular tricuspid pressure gradient could be measured in 95% patients who had TR that was more than mild but in only 36% of those who had TR that was mild or trivial.
Clinical, biological, and treatment characteristics of patients with right ventricular tricuspid pressure gradient
Comparisons of patients with and without HF and HF patients with (n ¼ 413) and without a measurement of RVTG (n ¼ 967) are shown in Table 1 . Among patients with HF, those with LVSD were slightly older, more likely to be men, to have IHD, and be in AF compared with those with PS-HF. Heart failure patients in whom RVTG could be measured were older, more often women, and more likely to have chronic obstructive pulmonary disease, PS-HF, and AF and less likely to have IHD or diabetes compared with those in whom it could not be measured. Patients with a measurement of RVTG also had a higher heart rate and NT-proBNP. The baseline characteristics of the 413 patients with HF and measured RVTG are shown divided by quartiles in Table 2 , with medical therapy shown in Supplementary material online.
Mortality
The median (IQR) follow-up period for the 2100 patients was 66 (56-74) months and, overall, 665 (32%) patients died. Mortality was greater in patients with PS-HF and LVSD compared with those without HF (x 2 from log-rank test ¼ 150.9; P , 0.0001;
figure not shown). Mortality was markedly increased in the fourth quartile of RVTG ( Figure 2) , with a steep increase in the probability of death when RVTG was plotted as a continuous variable ( Figure 3 ). There was no significant difference in prognosis between those patients in the first three quartiles of RVTG and those in whom no measurement of RVTG was possible 18 (17) 15 (14) 12 (12) 22 (22) Table 2 .
( Figure 2 ). In contrast, those in Quartile 4 (Q4) had a worse prognosis. Mortality was higher in Q4 vs. Q1-3 grouped together for patients with HF (figure not shown, x 2 from log-rank test ¼ 26.9; P ¼ 0 , 0.0001) both in patients with LVSD (x 2 from log-rank test ¼ 13.0; P , 0.000) or PS-HF (x 2 from log-rank test ¼ 4.6; P ¼ 0.03) subgroup. In Cox's regression analysis, RVTG was a strong independent prognostic marker, even in models including log NT-proBNP and other echo variables ( Table 5) .
Right ventricular tricuspid pressure gradient threshold and prevalence in left ventricular systolic dysfunction and preserved systolic heart failure Using a threshold value for RVTG of 25 mmHg, the median value in patients with a measurable RVTG, 46% of those with PS-HF, 50%
of those with LVSD, and 23% of those without HF would have been defined as PAH (Figure 4) . Using a threshold value for RVTG of 35 mmHg to define PAH, the value at which mortality increases steeply in patients with a measurable RVTG, the respective proportions were 30, 18, and 4% of those with LVSD, PS-HF, and no HF (Figure 4) . However, if all patients, including those in whom RVTG could not be measured, are considered, then only 6, 7, and 8% had RVTG . 35 mmHg ( Table 1) .
Echocardiographic variables and determinants of right ventricular tricuspid pressure increase
Echocardiographic variables by quartiles of RVTG are shown in Table 3 . In patients in the highest quartile of RVTG, LA area, LV end-diastolic volume, peak E velocity, E/A ratio, LV filling pressure, and severity of MR were all markedly increased and LVEF decreased. All the RV variables also worsened as RVTG increased. The independent predictors of Q4 vs. Q1 -3 of RVTG among the 413 patients with HF were: greater severity of MR, higher estimated LV filling pressure, more severe LVSD, and greater LVEDV ind . Age, sex, smoking, hypertension, diabetes, chronic obstructive pulmonary disease, IHD, type of HF, BMI, arrhythmia, heart rate, blood pressure, haemoglobin, and eGFR were not independent predictors ( Table 4) . Of note, RVTG did not correlate with FEV 1 /FVC (P ¼ 0.95) and poorly with FEV 1 (R 2 ¼ 0.02; P ¼
0.001).
Use of pulmonary arterial hypertension to diagnose heart failure or preserved systolic heart failure in symptomatic patients
Right ventricular tricuspid pressure gradient .35 mmHg had a 96% specificity to discriminate between those with and without HF in subjects with LVEF . 45% and measurable RVTG LV, left ventricle; LVEDV, LV end-diastolic volume; ind, indexed to body surface area; LA, left atria; E, early peak velocity of the mitral inflow; A, late peak velocity mitral inflow; DCT, deceleration time of the E; TAPSE, tricuspid annular plane systolic excursion; RV, right ventricle; other abbreviations as in Table 2 .
a In patients without AF.
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( Figure 4) . However, this value identified only 7% of all patients with PS-HF when patients in whom RVTG could not be measured were included ( Table 1) .
Discussion
In this analysis, TR could be detected in about 60% of the patients with and about 36% of those without HF and TRV could be measured in 30 and 13%, respectively. This is similar to the rate of RVTG measurement in other studies. 4 Tricuspid regurgitation volume suggesting a PASP of .45 mmHg was rare in patients without HF but moderately common in patients with HF. Pulmonary hypertension was associated with factors likely to cause raised pulmonary venous pressure, including the severity of MR, raised LV filling pressures, LV systolic dysfunction, and LV dilation. An RVTG . 35 mmHg ( PASP ¼ 45 mmHg) was an independent predictor of mortality in patients with HF even when adjusted for age, LV function, and NT-proBNP. Heart failure patients without measurable PASP had a prognosis similar to those with lower PA pressures suggesting, as might be expected, that undetectable TR is rare in patients with PAH and HF.
Determinants of and associations with pulmonary arterial pressure
Pulmonary arterial pressure is determined by pulmonary vascular resistance (PVR), pulmonary blood flow, and pulmonary venous pressure. Our study suggests that in patients with HF, factors associated with increased pulmonary venous pressure are the key determinants of PAH. Heart failure, MR and LV filling pressure have previously been shown to be determinants of RVTG in a selected LVSD population. 6 We have extended this finding to a broader spectrum of patients with HF. Although, NT-proBNP was not an independent predictor of PAH in a multivariable model, there was a strong association between NT-proBNP and quartile of TRV. Removing either LV filling pressure, MR class, or HF class each allowed NT-proBNP to enter the model, consistent with the view that these variables are associated with an increase in LA filling pressure and that this is a key determinant of PAH.
Although raised pulmonary venous pressure was the main determinant of PAH, this may lead to changes in pulmonary arteriolar tone 14 and structure. 15 In health, there is very little pre-capillary smooth muscle in the PA circulation but it hypertrophies in patients with HF. These secondary changes might be important in protecting the pulmonary capillary circulation from high PA pressures and reducing the risk of pulmonary oedema. However, these changes probably cause pulmonary hypertension to become relatively fixed, so that the correction of pulmonary venous hypertension does not lead to the resolution of PAH and may ultimately lead to a 'vicious cycle' whereby PAH gets progressively worse independent of pulmonary venous pressures. On the other hand, we did not find airways function, measured by spirometry, to be a determinant of PAH. 16 Patients with HF and chronic obstructive pulmonary disease do have a worse prognosis, but this may be mediated through other mechanisms than PAH. 17 Patients with PAH had more severe symptoms, reduced exercise capacity, and evidence of RV dysfunction. These may well be consequences rather than causes of PAH. Pulmonary arterial hypertension may limit the rise in pulmonary blood flow during exercise and impair alveolar -capillary gas exchange, 18 thereby limiting exercise capacity. Right ventricular dysfunction might be expected to be associated with reduced cardiac output and pulmonary blood flow. Pulmonary vascular resistance may be underestimated in these circumstances.
Pulmonary arterial pressure and prognosis
We showed that PAH is a strong predictor of mortality in HF and that this was independent of another powerful predictor, log NT-pro-BNP, and of echocardiographic variables associated with PA pressure. Few studies have analysed the prognostic value of PAH in HF 4 or, when they have, focused only LVSD or PS-HF patients. 1, 5, 7 The present study is the first to include such a broad range of variables and patients. Despite a strong association between PAH and RV dysfunction, both were included in the prognostic model. Patients with PAH and RV dysfunction had a particularly poor prognosis. 5 This could reflect intrinsic RV disease that Table 2 .
a All variables in Table 2 except 6 min walk test that was excluded due to a substantial amount of patients unable to complete it.
Determinants and prognostic value of PAH in HF patients has led to a greater decline in function for a given PASP. From this point of view, RV dysfunction is driving a worse prognosis. However, as noted above, RV dysfunction may lead to a decline in pulmonary blood flow and may be a signal that PASP is an underestimate of PVR. Patients with RV dysfunction are also likely to have higher RA pressures. If this is not taken into account, then PA pressure may again be underestimated. Accordingly, it is possible that RV dysfunction is included in the prognostic model because it corrects for these underestimations of PASP and PVR.
However, RV dysfunction, whether it is due to or independent of PASP and PVR, seems a plausible substrate both for worsening HF and arrhythmias leading to sudden death. The severity of MR was also a powerful determinant of PAH and an independent maker of prognosis as found in the previous work. 19 The finding suggests that MR alters the prognosis not only by increasing the RVTG but also perhaps by increasing LV dilation and dysfunction or directly altering PA function independent of pressure transfer. Abbreviations as in Table 2 . a All variables in Table 2 except 6 min walk test that was excluded due to a substantial amount of missing data.
Using prognosis to define pulmonary arterial hypertension
At present, PAH is defined empirically, rather than by the identification of a 'prognostic' threshold. In our study, PASP . 45 mmHg was a powerful predictor of death. Mild PAH, according to the ESC guidelines, is defined as an RVTG between 31 and 46 mmHg (corresponding to a PASP of 40-55 mmHg), 21 but this may reflect the young age of patients on which the recommendation is made. 3, 22 Pressure arterial systolic pressure increases with age. 3 A recent study of patients with PS-HF has shown that PASP . 48 mmHg estimated by echocardiography was strongly associated with mortality, 7 which is consistent with our findings. These data suggest that the thresholds used to define PAH in HF should be reviewed to align them with the growing body of evidence and to assist in defining populations who may be targets for specific treatment of PAH.
23,24
Pulmonary arterial hypertension prevalence in heart failure, left ventricular systolic dysfunction and preserved systolic heart failure
The prevalence of PAH in patients with HF is uncertain. The EuroHeart Failure Survey reported that 16% of the patients had PAH but provided no precise diagnostic criteria. 25 Our data suggest that the prevalence of prognostically adverse PAH is not high in the general population with HF. In our study, 25% of the HF patients with an RVTG measurement had an estimated PASP . 45 mmHg, but this represented only 7% of the total HF population. The numbers rise to 50% of the patients with an RVTG measurement if a lower value for PASP of 35 mmHg is used, which is very similar to another study 4 in which RVTG measurements were possible in 38% of the patients with HF, compared with 30% in our population. However, this represents only 14% of the overall population with HF. In our study, the prevalence of PASP . 45 mmHg was similar in patients with PS-HF and LVSD whether or not RVTG could be measured (Table 1) . However, RVTG could be measured in a higher proportion of those with PS-HF (40%) compared with LVSD (26%) and therefore a PASP of .45 mmHg was more common in patients with LVSD when the analysis was restricted to those in whom RVTG could be measured ( Table 4 ). The prevalence of PAH has also been described in two previous studies of PS-HF using a threshold of PASP of 35 mmHg. Klapholz et al. 26 studied 619 patients with PS-HF and reported a prevalence of PAH of 44%, which is similar to our population. This contrasts with a rate of 83% in a study of 244 patients with PS-HF. 7 Our data show that the threshold used to define PAH and the method of patient selection are critically important determinants of prevalence. Selecting only patients in whom RVTG can be measured will lead to a severe overestimation of prevalence. Pulmonary arterial hypertension may not just be a marker of more severe cardiac dysfunction but could also be one of the mechanisms by which HF progresses and therefore a target for therapy. Studies of endothelin antagonists, agents that appear useful in primary PAH, have suggested little benefit and possible harm in patients with HF and LVSD. However, these studies did not target what might be the rather modest proportion of patients with HF and prognostically adverse PAH. A series of studies have investigated the effects of phosphodiesterase-V inhibitors in patients with HF and suggested benefit, especially in patients with PAH. 24 Pulmonary arterial hypertension may also be a target for new classes of agents, such as soluble guanylate cyclase activators. 27 
Limitation
We defined PS-HF as a clinical diagnosis of HF in patients with an LVEF . 45% and an elevated NT-proBNP. This may not have excluded patients with other causes of PAH. The most likely alternative cause for PAH is chronic obstructive pulmonary disease and NT-proBNP may also be elevated in this setting, although levels are generally not as high as seen in HF. 28 However, chronic obstructive pulmonary disease was no more common in patients with PAH than in other patients with HF. Finally, none of our patients were assessed for sleep-disordered breathing, which might cause PAH by inducing hypoxia and pulmonary vasoconstriction. 29 The lack of measurement of pulmonary blood flow or accurate measurements of atrial pressures are a further limitation. The measurement of outflow tract velocities or pulmonary venous flow patterns may have improved accuracy but would have excluded many more patients from the analysis and are not practical in a busy clinical setting. We only attempted the measurement of PASP at rest. In health, PVR falls dramatically with exercise and therefore PASP changes little. In patients with HF, the fall in PVR may be impaired leading to further increases in PASP during exercise. The development of implantable haemodynamic systems to measure PA pressure both at rest and during exercise is of considerable scientific and, potentially, clinical interest. 30 
Conclusion
The prevalence of PAH in HF is highly dependent on patient selection and the threshold of PASP used. A PASP of .45 mmHg is associated with a worse prognosis in HF. The prevalence of prognostically important PAH may be ,10% and is strongly associated with factors that may cause pulmonary venous hypertension. Despite the powerful associations between PAH and other important determinants of prognosis such as MR, NT-proBNP, and RV and LV dysfunction, PAH remains an important independent predictor of mortality and could be a target for therapy, awaiting appropriately designed, randomized, controlled trials.
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